Oncocyte Corp Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2015 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Oncocyte Corp quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2015 to Q2 2024.
  • Oncocyte Corp Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $386K, a 53.7% decline year-over-year.
  • Oncocyte Corp Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $1.9M, a 74.6% decline year-over-year.
  • Oncocyte Corp annual Share-based Payment Arrangement, Expense for 2023 was $2.76M, a 72.5% decline from 2022.
  • Oncocyte Corp annual Share-based Payment Arrangement, Expense for 2022 was $10M, a 46.8% increase from 2021.
  • Oncocyte Corp annual Share-based Payment Arrangement, Expense for 2021 was $6.84M, a 35% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.9M $386K -$448K -53.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $2.34M $418K -$416K -49.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $2.76M $484K -$2.14M -81.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-16
Q3 2023 $4.9M $608K -$2.57M -80.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $7.47M $834K -$1.4M -62.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $8.87M $834K -$1.18M -58.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $10M $2.62M +$914K +53.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-16
Q3 2022 $9.13M $3.18M +$1.33M +71.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $7.8M $2.23M +$236K +11.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $7.56M $2.01M +$720K +55.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $6.84M $1.71M Oct 1, 2021 Dec 31, 2021 10-K 2023-04-12
Q3 2021 $1.85M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $2M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $1.29M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q1 2019 $101K -$245K -70.8% Jan 1, 2019 Mar 31, 2019 10-Q 2019-05-14
Q3 2018 $1.55M $345K -$117K -25.3% Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-13
Q2 2018 $1.67M $390K +$44K +12.7% Apr 1, 2018 Jun 30, 2018 10-Q 2018-08-14
Q1 2018 $1.63M $346K -$4K -1.14% Jan 1, 2018 Mar 31, 2018 10-Q 2018-05-15
Q4 2017 $1.63M $472K Oct 1, 2017 Dec 31, 2017 10-K 2018-04-02
Q3 2017 $462K +$204K +79.1% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 $346K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 $350K +$225K +180% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-15
Q3 2016 $258K -$423K -62.1% Jul 1, 2016 Sep 30, 2016 10-Q 2016-11-10
Q1 2016 $125K -$91K -42.1% Jan 1, 2016 Mar 31, 2016 10-Q 2017-04-28
Q3 2015 $681K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q1 2015 $216K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.